QSAM Biosciences Dette/Equité
Quel est le Dette/Equité de QSAM Biosciences?
Le Dette/Equité de QSAM Biosciences, Inc. est -3.34
Quelle est la définition de Dette/Equité?
Le ratio d'endettement et d'équité est un ratio financier indiquant la proportion relative des capitaux propres et de la dette utilisée pour financer les actifs d'une entreprise.
The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.
Dette/Equité des entreprises dans Health Care secteur sur OTC par rapport à QSAM Biosciences
Que fait QSAM Biosciences?
QSAM Biosciences, Inc., a clinical stage biotechnology company, develops drugs for the treatment of bone cancer. The company is involved in the development of CycloSam (Samaium-153 DOTMP), a clinical-stage novel radiopharmaceutical for the treatment of bone cancer and related diseases. It has a license agreement with IGL Pharma, Inc. The company was formerly known as Q2Earth, Inc. and changed its name to QSAM Biosciences, Inc. in September 2020. QSAM Biosciences, Inc. was founded in 2004 and is based in Austin, Texas.
Entreprises avec dette/equité similaire à QSAM Biosciences
- Nagarjuna Fertilizers and Chemicals a Dette/Equité de -3.35
- Bunker Hill Mining a Dette/Equité de -3.35
- Choom a Dette/Equité de -3.35
- Ascena Retail a Dette/Equité de -3.35
- Odyssey Marine Exploration a Dette/Equité de -3.35
- Lithium & Boron Technology a Dette/Equité de -3.34
- QSAM Biosciences a Dette/Equité de -3.34
- Surgalign a Dette/Equité de -3.34
- TOM a Dette/Equité de -3.33
- Emerge Commerce a Dette/Equité de -3.33
- Pioneer Distilleries a Dette/Equité de -3.32
- Teles Ag Inform.Tech.Konv a Dette/Equité de -3.32
- PTC Therapeutics Inc a Dette/Equité de -3.32